Medtronic plc (MDT) operating KPIs
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)
Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%
Medtronic neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M) ($M)
Legacy geographic split reported continuously from FY2016Q1 through FY2024Q4; replaced by unified International division tables starting FY2025Q1.
Latest, FY2024
1,362
Period ended Apr 30, 2024
Change on a year earlier
+6.2%
1,283 in FY2023
History
5 years
Since FY2020
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Apr 30, 2024 | 1,362 | +6.2% | Medtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗ |
| FY2023 | Apr 30, 2023 | 1,283 | +4.4% | Medtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗ |
| FY2022 | Apr 30, 2022 | 1,229 | +21.1% | Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗ |
| FY2021 | Apr 30, 2021 | 1,015 | +7.4% | Medtronic SEC 8K_EARNINGS — FY2022Q4 (filed 2022-05-26) ↗ |
| FY2020 | Apr 30, 2020 | 945 | – | Medtronic SEC 8K_EARNINGS — FY2021Q4 (filed 2021-05-27) ↗ |
Breakdown
What makes up neuroscience portfolio — emerging markets revenue (legacy through fy2024q4, $m)
Cite this data
StockData. (2026). Medtronic Neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M) ($M), annual FY2020–FY2024 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/neuro-port-em-leg-rev
See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.